A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Jiangsu Nutai Biologics Co., Ltd
Jiangsu Nutai Biologics Co., Ltd
University of Edinburgh
Ankara Etlik City Hospital
Norwegian University of Science and Technology
Pakistan Society of Pediatric Oncology
Pfizer
M.D. Anderson Cancer Center
Fujian Medical University
Helsinn Healthcare SA
Helsinn Healthcare SA
Hospital Beatriz Ângelo
Pfizer
Pfizer
University of Rochester
University of Copenhagen
University of Sao Paulo
Instituto do Cancer do Estado de São Paulo
National Institute of Allergy and Infectious Diseases (NIAID)
Université Catholique de Louvain
Wake Forest University Health Sciences
Wake Forest University Health Sciences
National Taiwan University Hospital
Hôpital Cochin
University of Rochester
Manchester University NHS Foundation Trust
Cedars-Sinai Medical Center
Baylor College of Medicine
Chung Shan Medical University
Cedars-Sinai Medical Center
CSL Behring
Karadeniz Technical University
Alliance for Clinical Trials in Oncology
University of Edinburgh
Mayo Clinic
Aalborg University Hospital
Chugai Pharma France
Swiss Cancer Institute
Norwegian University of Science and Technology
Iuliu Hatieganu University of Medicine and Pharmacy
Hospital Erasto Gaertner
University of Florida
Hospices Civils de Lyon
University of Erlangen-Nürnberg Medical School
Maastricht University Medical Center
University Hospital, Clermont-Ferrand
The University of Texas Medical Branch, Galveston
Wake Forest University Health Sciences
Ludwig-Maximilians - University of Munich
The University of Texas Medical Branch, Galveston
Helsinn Therapeutics (U.S.), Inc